Beata Krasińska1, Lech Paluszkiewicz2, Ewa Miciak-Ławicka3, Maciej Krasinski4, Piotr Rzymski5,6, Andrzej Tykarski3, Zbigniew Krasiński7. 1. Department of Hypertension, Angiology and Internal Diseases, Poznan University of Medical Sciences, Długa 1/2, 61-848, Poznań, Poland. beata.bkrasinska@gmail.com. 2. Department of Thoracic And Cardiovascular Surgery/Perioperative diagnostics Bad Oeynhausen, Heart and Diabetes Center NRW, Ruhr-University of Bochum, Bochum, Germany. 3. Department of Hypertension, Angiology and Internal Diseases, Poznan University of Medical Sciences, Długa 1/2, 61-848, Poznań, Poland. 4. Imperial College London School of Medicine, London, UK. 5. Department of Environmental Medicine, Poznan University of Medical Sciences, Poznan, Poland. 6. Integrated Science Association (ISA), Universal Scientific Education and Research Network (USERN), Poznan, Poland. 7. Department of General and Vascular Surgery, Poznan University of Medical Sciences, Poznan, Poland.
Abstract
PURPOSE: Time of drug administration may significantly influence its effect. The aim of the present study was to investigate the effect of ASA (administrated in the morning or in the evening) on the anti-hypertensive effect and diurnal blood pressure profile in the high-risk group of cardiovascular patients. METHODS:All patients (n = 114) had been diagnosed with coronary heart disease and arterial hypertension prior to the enrolment and had been treated with 75 mg per day of ASA in the morning. The patients were randomly assigned to one of the two study groups receiving 75 mg of ASA per day in a single antiplatelet therapy for 3 months in the morning (n = 58) or in the evening (n = 56). The control group (n = 61) consisted of patients with arterial hypertension but without coronary heart disease, not receiving ASA. In all the patients, during each visit, clinical blood pressure (BP) and ambulatory blood pressure measurements (ABPM) were performed. RESULTS: There was a significant reduction in 24-h BP and blood pressure at night in the ASA group evening group compared with the ASA morning group and the control group. CONCLUSIONS: The present study demonstrated that compared with the use of ASA in the morning, its administration in the evening may lead to favourable drop in the ABPM and an improvement of the diurnal profile in the high-risk group of cardiovascular patients who are not naïve to ASA.
RCT Entities:
PURPOSE: Time of drug administration may significantly influence its effect. The aim of the present study was to investigate the effect of ASA (administrated in the morning or in the evening) on the anti-hypertensive effect and diurnal blood pressure profile in the high-risk group of cardiovascular patients. METHODS: All patients (n = 114) had been diagnosed with coronary heart disease and arterial hypertension prior to the enrolment and had been treated with 75 mg per day of ASA in the morning. The patients were randomly assigned to one of the two study groups receiving 75 mg of ASA per day in a single antiplatelet therapy for 3 months in the morning (n = 58) or in the evening (n = 56). The control group (n = 61) consisted of patients with arterial hypertension but without coronary heart disease, not receiving ASA. In all the patients, during each visit, clinical blood pressure (BP) and ambulatory blood pressure measurements (ABPM) were performed. RESULTS: There was a significant reduction in 24-h BP and blood pressure at night in the ASA group evening group compared with the ASA morning group and the control group. CONCLUSIONS: The present study demonstrated that compared with the use of ASA in the morning, its administration in the evening may lead to favourable drop in the ABPM and an improvement of the diurnal profile in the high-risk group of cardiovascular patients who are not naïve to ASA.
Authors: P Verdecchia; G Schillaci; M Guerrieri; C Gatteschi; G Benemio; F Boldrini; C Porcellati Journal: Circulation Date: 1990-02 Impact factor: 29.690
Authors: Andrzej Tykarski; Krzysztof Narkiewicz; Zbigniew Gaciong; Andrzej Januszewicz; Mieczysław Litwin; Katarzyna Kostka-Jeziorny; Marcin Adamczak; Ludwina Szczepaniak-Chicheł; Marzena Chrostowska; Danuta Czarnecka; Grzegorz Dzida; Krzysztof J Filipiak; Jerzy Gąsowski; Jerzy Głuszek; Stefan Grajek; Tomasz Grodzicki; Kalina Kawecka-Jaszcz; Beata Wożakowska-Kapłon; Beata Begier-Krasińska; Jacek Manitius; Małgorzata Myśliwiec; Anna Niemirska; Aleksander Prejbisz; Danuta Pupek-Musialik; Grażyna Brzezińska-Rajszys; Katarzyna Stolarz-Skrzypek; Agnieszka Szadkowska; Tomasz Tomasik; Krystyna Widecka; Andrzej Więcek; Adam Windak; Jacek Wolf; Tomasz Zdrojewski; Aleksandra Żurowska Journal: Kardiol Pol Date: 2015 Impact factor: 3.108